The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Abstract
Combination chemotherapy and nanoparticle drug delivery are two areas that have shown significant promise in cancer treatment. Combined therapy of two or more drugs promotes synergism among the different drugs against cancer cells and suppresses drug resistance through distinct mechanisms of action. Nanoparticle drug delivery, on the other hand, enhances therapeutic effectiveness and reduces side effects of the drug payloads by improving their pharmacokinetics. These two active research fields have been recently merged to further improve the efficacy of cancer therapeutics. This review article summarizes the recent efforts in developing nanoparticle platforms to concurrently deliver multiple types of drugs for combination chemotherapy. We also highlight the challenges and design specifications that need to be considered in optimizing nanoparticle-based combination chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Self-citationMechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Nanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes
Olson, F., Hunt, C. A., Szoka, F. C., Vail, W. J., & Papahadjopoulos, D. (1979) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(79)90085-3 · Cited by 1,126
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 945
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 886
Self-citationChen, A. M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., & He, H. (2009) · Small · doi:10.1002/smll.200900621 · Cited by 671
Wang, Y., Gao, S., Ye, W.-H., Yoon, H. S., & Yang, Y.-Y. (2006) · Nature Materials · doi:10.1038/nmat1737 · Cited by 658
Greco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649
Stealth Me. PEG‐PLA Nanoparticles Avoid Uptake by the Mononuclear Phagocytes System
Bazile, D., Prud'homme, C., Bassoullet, M., Marlard, M., Spenlehauer, G., & Veillard, M. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840420 · Cited by 635
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Glantz, M., Jaeckle, K. A., Chamberlain, M. C., Phuphanich, S., Recht, L. D., Swinnen, L. J., Maria, B., LaFollette, S., Schumann, G. B., Cole, B. F., et al. (1999) · PubMed · Cited by 529
Chen, J., Chen, S., Zhao, X., Kuznetsova, L. V., Wong, S. S., & Ojima, I. (2008) · Journal of the American Chemical Society · doi:10.1021/ja805570f · Cited by 495
Ganta, S., & Amiji, M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800240j · Cited by 490
Paclitaxel-Functionalized Gold Nanoparticles
Gibson, J. D., Khanal, B. P., & Zubarev, E. R. (2007) · Journal of the American Chemical Society · doi:10.1021/ja075181k · Cited by 484
Zhu, C., Jung, S., Luo, S., Meng, F., Zhu, X., Park, T. G., & Zhong, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.077 · Cited by 440
Polymer−Cisplatin Conjugate Nanoparticles for Acid-Responsive Drug Delivery
Aryal, S., Hu, C.-M. J., & Zhang, L. (2010) · ACS Nano · doi:10.1021/nn9014032 · Cited by 400
Self-citationJudson, I., Radford, J. A., Harris, M., Blay, J.-Y., van Hoesel, Q., le Cesne, A., van Oosterom, A. T., Clemons, M. J., Kamby, C., Hermans, C., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00050-8 · Cited by 392
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., & Mayer, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 356
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Mayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., Ramsay, E. C., Bally, M. B., & Janoff, A. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0118 · Cited by 331
Polymer conjugates with anticancer activity
Putnam, D., & Kopeček, J. (1995) · Advances in Polymer Science · doi:10.1007/3540587888_14 · Cited by 315
Emilienne Soma, C., Dubernet, C., Bentolila, D., Benita, S., & Couvreur, P. (2000) · Biomaterials · doi:10.1016/s0142-9612(99)00125-8 · Cited by 281
Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates
Zhang, L., Radovic‐Moreno, A. F., Alexis, F., Gu, F. X., Basto, P. A., Bagalkot, V., Jon, S., Langer, R. S., & Farokhzad, O. C. (2007) · ChemMedChem · doi:10.1002/cmdc.200700121 · Cited by 257
Self-citationMechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine.
Nelson, J. A., Carpenter, J. W., Rose, L. M., & Adamson, D. J. (1975) · PubMed · Cited by 243
Sapra, P., & Allen, T. M. (2002) · PubMed · Cited by 242
Lammers, T., Subr, V., Ulbrich, K., Peschke, P., Huber, P. E., Hennink, W. E., & Storm, G. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.040 · Cited by 240
Aryal, S., Grailer, J. J., Pilla, S., Steeber, D. A., & Gong, S. (2009) · Journal of Materials Chemistry · doi:10.1039/b914071a · Cited by 226
Self-citationTherapeutic Nanoparticles to Combat Cancer Drug Resistance
Hu, C.-M., & Zhang, L. (2009) · Current Drug Metabolism · doi:10.2174/138920009790274540 · Cited by 223
Self-citationJohnson, S. M., Bangham, A. D., Hill, M. W., & Korn, E. D. (1971) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(71)90184-2 · Cited by 222
Batist, G., Gelmon, K. A., Chi, K. N., Miller, W. H., Chia, S. K. L., Mayer, L. D., Swenson, C. E., Janoff, A. S., & Louie, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0515 · Cited by 213
Song, X. R., Cai, Z., Zheng, Y., He, G., Cui, F. Y., Gong, D. Q., Hou, S. X., Xiong, S. J., Lei, X. J., & Wei, Y. Q. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.018 · Cited by 211
Targeted Paclitaxel by Conjugation to Iron Oxide and Gold Nanoparticles
Hwu, J. R., Lin, Y. S., Josephrajan, T., Hsu, M.-H., Cheng, F.-Y., Yeh, C.-S., Su, W.-C., & Shieh, D.-B. (2009) · Journal of the American Chemical Society · doi:10.1021/ja804947u · Cited by 199
Tong, R., & Cheng, J. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800491 · Cited by 190
Kaneshiro, T. L., & Lu, Z.-R. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.06.026 · Cited by 186
Systemic Toxic Effects Associated With High-Dose Verapamil Infusion and Chemotherapy Administration
Pennock, G. D., Dalton, W. S., Roeske, W. R., Appleton, C. P., Mosley, K., Plezia, P., Miller, T. P., & Salmon, S. E. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.2.105 · Cited by 185
Drug-Polymer Conjugates Containing Acid-Cleavable Bonds
Kratz, F., Beyer, U., & Schutte, M. T. (1999) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v16.i3.10 · Cited by 181
Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics
Tekade, R. K., Dutta, T., Gajbhiye, V., & Jain, N. K. (2009) · Journal of Microencapsulation · doi:10.1080/02652040802312572 · Cited by 181
Bae, Y., Diezi, T. A., Zhao, A., & Kwon, G. S. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.038 · Cited by 173
Wu, J. H., Lu, Y., Lee, A., Pan, X., Yang, X., Zhao, X. B., & Lee, R. J. (2007) · PubMed · Cited by 172
Ring-Opening Polymerization-Mediated Controlled Formulation of Polylactide−Drug Nanoparticles
Tong, R., & Cheng, J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja8084675 · Cited by 135
Tumor Priming Enhances Delivery and Efficacy of Nanomedicines
Lü, D., Wientjes, M. G., Lu, Z., & Au, J. L. ‐. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121632 · Cited by 128
Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs
Takakura, Y., & Hashida, M. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00131-c · Cited by 122
Tardi, P. G., Santos, N. D., Harasym, T. O., Johnstone, S. A., Zisman, N., Tsang, A. W., Bermudes, D. G., & Mayer, L. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0243 · Cited by 122
Tekade, R. K., Dutta, T., Tyagi, A., Bharti, A. C., Das, B. C., & Jain, N. K. (2008) · Journal of drug targeting · doi:10.1080/10611860802473154 · Cited by 115
Jaeckle, K. A., Batchelor, T. T., O'Day, S. J., Phuphanich, S., New, P., Lesser, G. J., Cohn, A. L., Gilbert, M. R., Aiken, R. D., Heros, D. O., et al. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1015752331041 · Cited by 113
Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer
Lu, Z., Tsai, M. C., Lü, D., Wang, J., Wientjes, M. G., & Au, J. L. ‐. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140095 · Cited by 105
Cao, S., & Rustum, Y. M. (2000) · PubMed · Cited by 104
Forssen, E. A., Malé-Brune, R., Adler‐Moore, J., Lee, M. J., Schmidt, P. G., Krasieva, T. B., Shimizu, S., & Tromberg, B. J. (1996) · PubMed · Cited by 103
Allémann, É., Brasseur, N., Benrezzak, O., Rousseau, J. A., Kudrevich, S. V., Boyle, R. W., Leroux, J., Gurny, R., & van Lier, J. E. (1995) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1995.tb05815.x · Cited by 101
Nanoparticle Albumin–Bound Paclitaxel for Metastatic Breast Cancer
Harries, M., Ellis, P., & Harper, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.002 · Cited by 100
Wong, M.-Y., & Chiu, G. N. C. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328336e940 · Cited by 90
Maladaptive Growth in the Failing Heart: The Cardiomyopathy of Overload
Katz, A. M. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1020604623427 · Cited by 88
Olafsen, T., Tan, G., Cheung, C. W., Yazaki, P. J., Park, J. M., Shively, J. E., Williams, L. E., Raubitschek, A. A., Press, M. F., & Wu, A. M. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh040 · Cited by 88
Hubert, A., Lyass, O., Pode, D., & Gabizón, A. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200002000-00009 · Cited by 87
Harasym, T. O., Tardi, P. G., Harasym, N. L., Harvie, P., Johnstone, S. A., & Mayer, L. D. (2006) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000006783980937 · Cited by 84
Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)
Guaglianone, P. P., Chan, K. K., Delaflor–Weiss, E., Hanisch, R., Jeffers, S., Sharma, D., & Muggia, F. M. (1994) · Investigational New Drugs · doi:10.1007/bf00874439 · Cited by 81
Pavillard, V., Kherfellah, D., Richard, S., Robert, J., & Montaudon, D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2027 · Cited by 59
Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors
Leyton, J. V., Olafsen, T., Sherman, M. A., Bauer, K. B., Aghajanian, P., Reiter, R. E., & Wu, A. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn055 · Cited by 43
Synergy Between 3′Azido-3′deoxythymidine and Paclitaxel in Human Pharynx FaDu Cells
Johnston, J. S., Johnson, A. D., Gan, Y., Wientjes, M. G., & Au, J. L. ‐. (2003) · Pharmaceutical Research · doi:10.1023/a:1024431218327 · Cited by 33
&NA; (2004) · Drugs in R&D · doi:10.2165/00126839-200405020-00012 · Cited by 13
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Cyclodextrin-based supramolecular systems for drug delivery: Recent progress and future perspective
Zhang, J., & Ma, P. X. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.001 · Cited by 836
Metadata
- Authors
- Hu, C.-M. J., Aryal, S., & Zhang, L.
- Venue
- Therapeutic Delivery
- Publisher
- Informa UK Limited
- Published
- 2010-08
- Volume
- 1
- Issue
- 2
- Pages
- 323-334
- ISSN
- 2041-5990 (ISSN-L)
- 2041-6008
- OpenAlex
- W2005433498
- Cited by
- 564
- References
- 71
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.